Comprehensive Genomic Profiling | DNA And RNA

Patients Results

Genomic Tests

Comprehensive Genomic Profiling using Next-Generation Sequencing with Machine/deep Learning

Solid Tumors

Next Generation Sequencing DNA & RNA Testing

Hematologic Tumors

Next Generation Sequencing DNA & RNA Testing

Solid Tumors

302 / >1600
DNA / RNA Genes

TAT

5-7 Days
Indications

All solid tumors Chromosomal abnormalities, gene amplifications, HRR,
MRD, Fusions: ALK, ROS1, RET,
NTRK1/2/3, and more.
BRAF, CIC, EWSR1, PD-L1, MET exon
14 skipping and various alternative
splicing, MET, HER2, PIK3CA, PTEN,
Gene amplifications, AKT1, RAS,
HER2, MYC, EGFR,
TTV,
T- & B-cell clonality analysis
Sample Type

Peripheral blood
Sample Requirements

Peripheral blood: 8-10 ml.
EDTA tube preferred
Results Reported

DNA+RNA
Monitoring
Therapeutic
Prognostic
Heterogeneity
Clinical Trial Matching

434 / >1600
DNA / RNA Genes

TAT

7-10 Days
Indications

All solid tumors
Fusions: ALK, ROS1, RET,
NTRK1/2/3, and more.
BRAF, CIC, EWSR1, PD-L1, MET exon
14 skipping and various alternative
splicing, MET, HER2, EGFR,
Gene amplifications, PIK3CA, PTEN, TTV,
AKT1, RAS and HRD
Cancer of unknown primary (CUP)
T- & B-cell clonality analysis
Sample Type

FFPE
Sample Requirements

1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported

DNA+RNA
Diagnostic
Therapeutic
Prognostic
Heterogeneity
Clinical Trial Matching

434
DNA Genes

TAT

5-7 Days
Indications

All solid tumors:
Mutations in 434 genes, copy number
variation and chromosomal structural
abnormalities, TMB, MSI, HRD
Sample Type

FFPE
Sample Requirements

1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported

DNA
Diagnostic
Therapeutic
Prognostic
Heterogeneity
Clinical Trial Matching

>1600
RNA Genes

TAT

7-10 Days
Indications

All Solid tumors:
Fusion: ALK, ROS1, RET, BRAF,
NTRK1/2/3, FGFR1/2/3/4, CIC,
EWSR1 & other sarcoma genes
Expression: PD-L1, MYC, CCND1,
MET, FGFR1/2/3/4, Ki67, ERBB2, MDM2
Alternative splicing: MET exon 14
skipping, EGFRvIII, NTRK,
Mutations in more than 1600 genes, TTV,
T- & B-cell clonality analysis
Sample Type

FFPE
Sample Requirements

1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported

RNA
Diagnostic
Therapeutic
Prognostic
Heterogeneity
Clinical Trial Matching

Hematology

302 / >1600
DNA / RNA Genes

TAT

5-7 Days
Indications

All hematologic neoplasms
including lymphoma
multiple myeloma, acute lymphoblastic
leukemia, acute myeloid leukemia, MDS, TTV,
CMML, MPN, MRD, VEXAS syndrome, and EBV
Chromosomal abnormalities, and gene amplifications,
T- & B-cell clonality analysis
Sample Type

Peripheral blood
Sample Requirements

Peripheral blood: 8-10 ml.
EDTA tube preferred
-
Results Reported

DNA+RNA
Diagnostic
Therapeutic
Prognostic
Heterogeneity
Clinical Trial Matching

302 / >1600
DNA / RNA Genes

TAT

7-10 Days
Indications

All hematologic neoplasms including lymphoma
Classification and diagnosis of lymphoma,
multiple myeloma, acute lymphoblastic
leukemia, and acute myeloid leukemia
Includes IgVH
Chromosomal abnormalities, and gene amplifications, TTV,
T- & B-cell clonality analysis
Sample Type

Bone marrow,
Peripheral blood,
Fresh tissue
Sample Requirements

Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported

DNA+RNA
Diagnostic
Therapeutic
Prognostic
Heterogeneity
Clinical Trial Matching

302
DNA Genes

TAT

5-7 Days
Indications

All hematologic neoplasms
including lymphoma
MDS, CMML, AML, MPN (JAK2, CALR, MPL),
MRD, multiple myeloma, and other
hematologic diseases
Sample Type

Bone marrow,
Peripheral blood,
Fresh tissue
Sample Requirements

Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported

DNA
Diagnostic
Therapeutic
Prognostic
Heterogeneity
Clinical Trial Matching